Clinical trials, such as NCT03203369 and NCT04109482, are actively assessing the efficacy of anti-CD123 CAR T cells for BPDCN treatment, although the submission of results is still pending, according to ClinicalTrials.gov. This evidence concerns the gene IL3RA and CD4+/CD56+ hematodermic neoplasm.